Nykode U.S. Patent for individualized VB10.NEO cancer vaccine program

  USPTO issues U.S. Patent No. 12,697,377 B2, covering Nykode's individualized

neoantigen therapy VB10.NEO and related modular neoantigen-based DNA vaccine
designs
• Patent provides protection through January 5, 2037, complementing a U.S.
patent granted in 2024 covering VB10.NEO
• Recent positive Phase 3 data from Merck and Moderna's individualized
neoantigen therapy program underscores a growing momentum for the INT field
• Nykode's VB10.NEO program provides an attractive alternative to mRNA based
vaccines enabling expansion to broad set of indications with a reliable and
economically supply chain.

https://www.marketscreener.com/news/nykode-therapeutics-receives-new-u-s-patent-strengthening-intellectual-property-protection-for-it-ce7859d3da81f62d